HC Wainwright Reaffirms Buy Rating for OptiNose (NASDAQ:OPTN)

OptiNose (NASDAQ:OPTN)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $5.00 price objective on the stock.

OptiNose Price Performance

Shares of OPTN stock opened at $0.46 on Wednesday. The company has a fifty day moving average price of $0.76 and a two-hundred day moving average price of $0.96. OptiNose has a one year low of $0.44 and a one year high of $2.10. The stock has a market cap of $68.60 million, a P/E ratio of -1.60 and a beta of -0.07.

Institutional Trading of OptiNose

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in OptiNose by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 4,242,610 shares of the company’s stock valued at $6,194,000 after acquiring an additional 62,906 shares during the period. Oracle Investment Management Inc. bought a new position in shares of OptiNose in the first quarter valued at about $474,000. Rosalind Advisors Inc. raised its position in shares of OptiNose by 66.2% in the second quarter. Rosalind Advisors Inc. now owns 7,547,148 shares of the company’s stock valued at $7,849,000 after purchasing an additional 3,005,659 shares during the period. Easterly Investment Partners LLC lifted its stake in shares of OptiNose by 10.2% during the 2nd quarter. Easterly Investment Partners LLC now owns 2,246,224 shares of the company’s stock worth $2,336,000 after buying an additional 208,185 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of OptiNose by 2.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,920,309 shares of the company’s stock worth $3,037,000 after buying an additional 81,233 shares during the period. 85.60% of the stock is owned by institutional investors and hedge funds.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.